<DOC>
	<DOCNO>NCT00745485</DOCNO>
	<brief_summary>1 . The study assess safety tolerability single-infusion zoledronic acid 5 mg administer private medical practice set nurse provide nationwide infusion service . Safety data largely monitor investigating change patient ' well-being study . 2 . The study pilot test Patient Registry Infusion Service process , allow zoledronic acid administer trial patient investigator ' private room team rove nurse .</brief_summary>
	<brief_title>Feasibility Doctors ' Rooms-based Infusion Zoledronic Acid</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>1 . Female menopause osteoporosis either : 70 year age old bone mineral density Tscore 3.0 less OR fracture due minimal trauma . 1 . Intravenous bisphosphonate within past 12 month 2 . Abnormal level protein urine via dipstick screening cause bacterial infection 3 . Abnormal liver function test great twice normal 4 . Evidence high bone turnover 5 . Abnormal calcium blood level 6 . Low Vitamin D level 7 . Poor renal function 8 . Abnormal parathyroid function uncontrolled , abnormal thyroid function 9 . History eye inflammation 10 . History diabetes lead kidney eye problem 11 . A history cancer except noninvasive cancer skin , colon , breast cervix 12 . Patients severe dental problem current dental infection Or require dental surgery 13 . Known sensitivity zoledronic acid bisphosphonates Other protocol define inclusion/exclusion criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Osteoporosis</keyword>
	<keyword>zoledronic acid</keyword>
	<keyword>postmenopausal woman</keyword>
</DOC>